Fertility in young-onset colorectal patients with cancer: a review
Fertility preservation is an important issue in patients with young-onset colorectal cancer. This article reports the effects of different treatments on fe
Related Articles
Ifinatamab Deruxtecan Shows “Promising Efficacy” in Pretreated ES-SCLC
Ifinatamab deruxtecan has demonstrated antitumor activity as second-line or later therapy in patients with ES-SCLC.
MD Anderson and Rice launch initiative to advance cancer-focused operations research
The University of Texas MD Anderson Cancer Center and Rice University today announced the launch of the Center for Operations Research in Cancer, a joint…
Sacituzumab Govitecan May Benefit Certain Patients With Metastatic NSCLC
Sacituzumab govitecan may provide an improvement in OS over docetaxel in patients with metastatic NSCLC whose disease did not respond to their last anti-PD-(L)1-containing regimen.
AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer
Join the AACR for its Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer, November 14-17, 2024.
Pathway to Developing Predictive Biomarkers for Immune Checkpoint Inhibitors in NSCLC
Researchers may have uncovered a metabolic pathway that could lead to the development of predictive biomarkers for immune checkpoint inhibitors in NSCLC, according to findings…
Join FDA for National Hispanic/Latino Family Cancer Awareness Week
FDA will hold the first National Hispanic/Latino Family Cancer Awareness Week to increase cancer awareness within the Hispanic/Latino population.
Meet the Team Dedicated to Keeping Moffit Clean and Safe
The Environmental Services team ensures infection prevention and patient satisfaction
Lock
Developing and Retaining a Robust and Diverse Cancer Workforce: Challenges and Opportunities Across the National Cancer Program
Precision oncology across the ages: Impact on children, adolescents, and young adults
Precision oncology endeavors to tailor therapies based on individual patient and tumor characteristics. This rapidly evolving field has transformed cancer treatment across all age groups.…
Dana-Farber President and CEO Laurie Glimcher, MD, Announces Her Plans to Step Down Capping a Highly Successful Tenure Marked with Discovery and Innovation
Laurie H. Glimcher, MD, announced today that she will step down as Dana-Farber Cancer Institute President and CEO on October 1, 2024, and will assume…
